Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Assets (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Return on Assets data on record, last reported at 0.0% in Q4 2025.

  • For Q4 2025, Return on Assets rose 135.0% year-over-year to 0.0%; the TTM value through Dec 2025 reached 0.0%, up 135.0%, while the annual FY2025 figure was 0.0%, 85.0% up from the prior year.
  • Return on Assets reached 0.0% in Q4 2025 per AMLX's latest filing, up from 0.53% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.1% in Q4 2023 and bottomed at 1.36% in Q4 2024.
  • Average Return on Assets over 4 years is 0.54%, with a median of 0.57% recorded in 2022.
  • Peak YoY movement for Return on Assets: plummeted -145bps in 2024, then soared 135bps in 2025.
  • A 4-year view of Return on Assets shows it stood at 0.7% in 2022, then surged by 114bps to 0.1% in 2023, then tumbled by -1518bps to 1.36% in 2024, then soared by 100bps to 0.0% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Assets were 0.0% in Q4 2025, 0.53% in Q3 2025, and 0.9% in Q2 2025.